A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use.
Saved in:
| Title: | A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use. |
|---|---|
| Authors: | Merenlender Wagner A; Teva Pharmaceutical Industries Ltd., Quantitative Pharmacology and Biosimilar Sciences, 12 Hatrufa Street, 42504, Netanya, Israel. Avia.MerenlenderWagner@teva.co.il., Perlstein I; Magic Wand Research LLC, Philadelphia, PA, USA., Farkas P; Teva PLIVA Croatia Ltd, Research and Development, Zagreb, Croatia., Lamson M; Nuventra Pharma Sciences, Pharmacokinetics and Clinical Pharmacology, Carrboro, NC, USA., Loupe P; Teva Branded Pharmaceutical Products LLC, West Chester, PA, USA., Spiegelstein O; Teva Pharmaceutical Industries Ltd., Quantitative Pharmacology and Biosimilar Sciences, 12 Hatrufa Street, 42504, Netanya, Israel., Kalmanczhelyi A; Teva Pharmaceutical Works Private Ltd., Debrecen, Hungary., Tiver R; Teva Branded Pharmaceutical Products LLC, West Chester, PA, USA., Franzenburg KR; Teva Branded Pharmaceutical Products LLC, West Chester, PA, USA., Harary E; Teva Pharmaceutical Industries Ltd., Quantitative Pharmacology and Biosimilar Sciences, 12 Hatrufa Street, 42504, Netanya, Israel., Elgart A; Teva Pharmaceutical Industries Ltd., Quantitative Pharmacology and Biosimilar Sciences, 12 Hatrufa Street, 42504, Netanya, Israel. |
| Source: | CNS drugs [CNS Drugs] 2026 Aug; Vol. 40 (8), pp. 1165-1177. Date of Electronic Publication: 2026 Jun 15. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9431220 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1934 (Electronic) Linking ISSN: 11727047 NLM ISO Abbreviation: CNS Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
